ABBV-400 在晚期结直肠癌中表现出初步疗效和安全性 根据一项1期试验(NCT05029882)的数据,ABBV-400是一种新型c-Met靶向抗体-药物缀合物,具有初步的抗肿瘤活性,并且在BRAF野生型、微卫星稳定(MSS)/错配修复熟练(pMMR)晚期结直肠癌(CRC)患者中是可耐受的,这些患者在先前的治疗中出现进展。 在2024年ASCO年会上发表...
一项1期试验(NCT05029882)的数据显示,靶向c-Met的新型ADC药物ABBV-400在BRAF野生型、微卫星稳定型(MSS)/错配修复良好型(pMMR)晚期结直肠癌(CRC)患者中显示出初步的抗肿瘤活性,且患者耐受性良好。港安健康国际医疗介绍,ABBV-400将c-Met靶向抗体telisotuzumab与拓扑异构酶1抑制剂有效载荷相结合。c-Met的过表达在...
Part3:ABBV-400单药,晚期胃食管腺癌/胃食管交界处腺癌GEA,先前至少接受1线化疗后进展,不超过2线化疗; Part4:ABBV-400单药,未携带BRAF V600E突变和dMMR+/MSI-Hi晚期CRC; Part5:ABBV-400单药,MET扩增,不限癌种; Part6:ABBV-400单药,MET突变,不腺癌...
ABBV-400由c-Met靶向抗体telisotuzumab与新型拓扑异构酶1抑制剂有效载荷共轭而成。现在介绍的治疗CRC的剂量升级(ESC)和扩增(EXP)队列数据。研究方法:试验期间,CRC患者被随机分配接受剂量分别为1.6mg/kg、2.4mg/kg和3.0mg/kgQ3W的ABBV-400。主要终点:ABBV-400的安全性、耐受性、药代动力学初步疗效和推荐的2期剂量...
https://www.onclive.com/view/telisotuzumab-adizutecan-represents-a-novel-c-met-targeting-adc-in-met-amplified-crc 编者按 如果您希望了解更多癌症等重大、复杂疾病的海外前沿研究成果、药物、疗法信息,请扫描下方二维码联系我们,盛诺...
The study is also evaluating ABBV-400 with bevacizumab in pts with CRC.Clinical trial information: NCT05029882.Preliminary efficacy outcomes.CRC Dosing Cohorts1.6 mg/kg Q3W(n = 32)2.4 mg/kg Q3W(n = 40)3.0 mg/kg Q3W(n = 41)Confirmed ORR, n (%)06 (15)8 (20)CBR12, n (%)11 (...
一项1期试验(NCT05029882)的数据显示,靶向c-Met的新型ADC药物ABBV-400在BRAF野生型、微卫星稳定型(MSS)/错配修复良好型(pMMR)晚期结直肠癌(CRC)患者中显示出初步的抗肿瘤活性,且患者耐受性良好。港安健康国际医疗介绍,ABBV-400将c-Met靶向抗体telisotuzumab与拓扑异构酶1抑制剂有效载荷相结合。c-Met的过表达在...
ABBV-400 conjugate average concentration was a better predictor of response and showed that higher exposure correlated with higher probability of response (n=122 CRC, ORR, p < 0.05) and safety events (n=204, Gr 鈮 3 neutropenia, anemia and thrombocytopenia, p < 0.001). Dose intensity ...
TPS3636#Background:Colorectal cancer (CRC) is the third most common cancer. In the metastatic (m) setting, the 5-year relative overall survival is approximately 15%. Conventional treatment comprises fluorouracil (5-FU)–based chemotherapy. Recently, targeted therapies have been studied for specific...